Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Augmedix Inc (NASDAQ: AUGX) was $2.53 for the day, down -6.64% from the previous closing price of $2.71. In other words, the price has decreased by -$6.64 from its previous closing price. On the day, 0.88 million shares were traded. AUGX stock price reached its highest trading level at $2.79 during the session, while it also had its lowest trading level at $2.5.
Ratios:
Our analysis of AUGX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.41 and its Current Ratio is at 2.41. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 0.83.
On December 15, 2023, Evercore ISI started tracking the stock assigning a In-line rating and target price of $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 15 ’24 when Shakil Ian sold 500 shares for $3.80 per share. The transaction valued at 1,900 led to the insider holds 3,000 shares of the business.
Shakil Ian sold 19,544 shares of AUGX for $74,590 on Apr 12 ’24. The CHIEF STRATEGY OFFICER now owns 3,000 shares after completing the transaction at $3.82 per share. On Apr 11 ’24, another insider, Shakil Ian, who serves as the CHIEF STRATEGY OFFICER of the company, sold 24,778 shares for $3.93 each. As a result, the insider received 97,477 and left with 3,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUGX now has a Market Capitalization of 123311440 and an Enterprise Value of 102940536. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.76 while its Price-to-Book (P/B) ratio in mrq is 5.27. Its current Enterprise Value per Revenue stands at 2.295 whereas that against EBITDA is -5.822.
Stock Price History:
The Beta on a monthly basis for AUGX is 0.53, which has changed by -0.20937502 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, AUGX has reached a high of $6.25, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is -33.04%, while the 200-Day Moving Average is calculated to be -45.82%.
Shares Statistics:
AUGX traded an average of 366.66K shares per day over the past three months and 306430 shares per day over the past ten days. A total of 48.61M shares are outstanding, with a floating share count of 43.96M. Insiders hold about 10.23% of the company’s shares, while institutions hold 74.98% stake in the company. Shares short for AUGX as of 1713139200 were 1237605 with a Short Ratio of 3.38, compared to 1710460800 on 747989. Therefore, it implies a Short% of Shares Outstanding of 1237605 and a Short% of Float of 4.4899996.
Earnings Estimates
The market rating of Augmedix Inc (AUGX) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.17, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.44 and -$0.58 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.35, with 4.0 analysts recommending between -$0.27 and -$0.44.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $13.5M to a low estimate of $13.1M. As of the current estimate, Augmedix Inc’s year-ago sales were $9.63MFor the next quarter, 6 analysts are estimating revenue of $14.59M. There is a high estimate of $14.7M for the next quarter, whereas the lowest estimate is $14.4M.
A total of 6 analysts have provided revenue estimates for AUGX’s current fiscal year. The highest revenue estimate was $62M, while the lowest revenue estimate was $60.34M, resulting in an average revenue estimate of $61.15M. In the same quarter a year ago, actual revenue was $44.85MBased on 5 analysts’ estimates, the company’s revenue will be $85.1M in the next fiscal year. The high estimate is $87M and the low estimate is $83.39M.
